We reviewed the top telehealth clinics prescribing sermorelin therapy, comparing physician credentials, dosing protocols, lab monitoring, pricing, and pharmacy standards. The goal is a factual basis for choosing a provider, not a referral list.
US telehealth clinics scored on medical oversight, pharmacy sourcing, pricing transparency, and lab monitoring.
Sermorelin and bioidentical hormone therapy for women's health optimization
This site is for informational purposes only and does not constitute medical advice. Sermorelin is a prescription medication that must be prescribed and supervised by a licensed physician. Full medical disclaimer
Sermorelin is a synthetic 29-amino acid analog of endogenous growth hormone-releasing hormone (GHRH), the peptide the hypothalamus secretes to signal the anterior pituitary to release human growth hormone. It is not synthetic HGH. Sermorelin acts upstream, on the pituitary gland itself, bypassing the hypothalamus.
Growth hormone secretion drops with aging (somatopause), with IGF-1 levels falling across middle and later adulthood. Sermorelin therapy restores the GHRH signal, signaling to the pituitary gland to resume more regular GH pulsation. The key pharmacological difference from exogenous somatropin is that the somatostatin feedback axis stays active throughout treatment, so GH output is capped by the patient’s own physiology rather than set entirely by the injected dose.
After subcutaneous injection, sermorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary[1], triggering a pulsatile release of endogenous growth hormone.
The released growth hormone circulates to the liver, where it stimulates production of IGF-1 (insulin-like growth factor 1)[6]. IGF-1 mediates the downstream effects: lean mass support, lipolysis[7], and tissue repair.
Sermorelin does not bypass pituitary gland functioning. The somatostatin axis stays intact and moderates GH output[1] based on circulating levels. This self-limiting mechanism is absent with exogenous somatropin, which is why sermorelin carries a lower side-effect burden at therapeutic doses.
Sermorelin does not deliver growth hormone directly. It stimulates the pituitary gland to produce GH physiologically, which means the body regulates output through its normal feedback systems. The result is a gradual restoration of GH pulsation, rather than a spike, and clinical outcomes reflect that steady trajectory.
GHRH-analog therapy reduces visceral adipose tissue over a 6-month protocol. Tesamorelin trials showed VAT reduction at 6 months in adults who have abdominal fat accumulation.
Stanley TL, Growth Hormone & IGF Research 2015Growth hormone supplementation in older men is associated with approximately 2 kg lean mass gain alongside fat mass reduction in controlled studies.
Growth Hormone in the Aging Male, 2013GHRH analog therapy produces measurable IGF-1 elevation within 2 weeks of starting a correct bedtime protocol.
Sinha et al., Transl Androl Urol 2020IGF-1 levels remain elevated through approximately 12 weeks of consistent therapy. The 90-day mark is the typical interval for assessing therapeutic response.
Sinha et al., Transl Androl Urol 2020Individual results depend on baseline IGF-1 levels, prescribed dose, protocol duration, sleep quality, protein intake, and training volume. Body composition changes are typically measurable at 3 months and most significant at 6 months. Sleep and energy improvements are usually the first outcomes patients report[15].
3 Month Deal For $89
Check EligibilityCompounded sermorelin through a telehealth provider runs $79 – $329 per month. The spread is driven by prescribed dose, whether quarterly IGF-1 monitoring is bundled in, and whether combination peptides are included. Here is what each price tier actually covers.
Best for: First-time users, cost-sensitive patients
Best for: Most patients. Best balance of cost and clinical oversight
Best for: Patients wanting full hormone optimization
Higher doses (200–300 mcg/day) cost more than starter doses (100 mcg/day).
Providers that include quarterly IGF-1 panels charge more but deliver better outcomes.
Adding ipamorelin or CJC-1295 to a sermorelin protocol increases cost but amplifies GH pulse.
Dedicated health coaches, unlimited messaging, and faster Rx turnaround come at a premium.
Most insurance plans do not cover compounded sermorelin. HSA/FSA funds are accepted by most providers.
Most patients tolerate sermorelin well. Side effects are typically dose-related and most pronounced during the first few weeks of treatment as the body adapts. Because sermorelin preserves the somatostatin feedback axis, the risks of GH oversaturation and the associated adverse effects of exogenous HGH are significantly reduced at therapeutic doses[15].
Mild side effects usually resolve within weeks 2–4 as your body adjusts.
Pain, redness, or swelling at the injection site. The FDA-approved Geref label[3] identifies this as the most common treatment-related adverse event (occurring in about 1 patient in 6).
Mild warmth or facial flushing shortly after injection. Listed in the Geref prescribing information[3] as an uncommon adverse event (<1% incidence) in sermorelin clinical trials.
Listed in the Geref label[3] as an uncommon adverse event (<1% incidence) in clinical trials.
Uncommon adverse events (<1% incidence) reported during clinical trials of sermorelin acetate in the Geref label[3] and in some evidence-based studies[1].
The decision to take sermorelin requires a comprehensive medical evaluation before starting treatment.
Swelling of the face, mouth, lips, or tongue, hives, or difficulty breathing are signs of a serious reaction, requiring emergent medical attention.
The risks of taking sermorelin in patients with chronic medical problems are not well studied. Treatment should only be started on the advice of a physician.
Every safe sermorelin program begins with a physician evaluation. Disclose your full medical history and current medications before starting. Patients on glucocorticoids or thyroid medications may require dose adjustments due to GH axis sensitivity interactions and may not be appropriate candidates. See clinical safety review →
Sermorelin is injected subcutaneously once daily, typically at bedtime to align with the natural growth hormone pulse that occurs during slow-wave sleep. Physicians usually start patients on low doses and titrate the dosing based on 90-day IGF-1 results and symptom response.
Add bacteriostatic water to the lyophilized (freeze-dried) sermorelin vial as directed. Swirl gently; do not shake. Reconstituted vials must be refrigerated per Geref prescribing information[3].
Use a 4–8 mm, 29–31 gauge insulin syringe[8] (per Forum for Injection Technique guidance). Your prescribed dose is set by your physician based on individual evaluation. Adult dose ranges used in telehealth practice are off-label, as the FDA-approved Geref label dosing is pediatric (30 mcg/kg) or diagnostic (1 mcg/kg IV).
Inject into the periumbilical abdomen or lateral thigh. Pinch the skin, insert at a 45° angle, and inject slowly. Rotate injection sites. Bedtime timing aligns with the natural post-sleep-onset GH pulse[9] (Spiegel et al., 2000).
Your physician will order an IGF-1 panel at the 90-day mark. Dose adjustments are made based on lab results and symptom response. IGF-1 elevation can occur within 2 weeks of starting GHRH-analog therapy, with the response holding through approximately 12 weeks[2].
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Week 1–4 | 100 mcg | Once daily | Starter dose. Assess tolerance. |
| Week 5–12 | 150–200 mcg | Once daily | Titrate based on response. |
| Month 4–6 | 200–300 mcg | Once daily | Adjust based on 90-day IGF-1. |
| Maintenance | Physician-guided | Once daily or 5 days on / 2 off | Long-term maintenance protocol. |
Doses and schedules shown are for informational purposes only. All sermorelin protocols must be prescribed and supervised by a licensed physician based on your individual IGF-1 levels, health history, and treatment goals.
Sermorelin is prescribed as a standalone therapy or combined with other peptides to amplify the GH pulse. The right protocol depends on your baseline IGF-1 and your treatment goals.
GHRH analog: stimulates pituitary GH release
Best for: First-time peptide users, patients with mild-to-moderate GH decline, conservative protocols
GHRH analog + GHRP: stimulates GH via synergistic pituitary pathways
Best for: Patients wanting GH stimulation through two pathways without cortisol or prolactin elevation from older GHRPs
GHRH + long-acting GHRH analog: sustained GH elevation
Best for: Patients preferring less frequent dosing, those focused on body composition and recovery
GHRH + GHRP + long-acting GHRH analog: multi-pathway GH stimulation
Best for: Patients with significant GH decline, advanced protocols, performance or longevity goals (off-label use)
| Factor | Sermorelin Monotherapy | Sermorelin + Ipamorelin | Sermorelin + CJC-1295 | Sermorelin + Ipamorelin + CJC-1295 |
|---|---|---|---|---|
| GH Pulse Strength | Moderate | High | Sustained | Highest |
| Dosing Frequency | Daily | Daily | Weekly | Daily/Split |
| IGF-1 Response | Moderate | High | High | Highest |
| Cost | $ | $$ | $$ | $$$ |
| Cortisol Risk | None | None | None | None |
| Best for Beginners | Yes | Yes | No | No |
All protocols require a physician prescription and baseline IGF-1 testing. Monotherapy with sermorelin or combination stacks should only be initiated after a comprehensive medical evaluation. Combination therapy should only be considered when a clinical evaluation confirms that monotherapy is insufficient for the patient's goals. Not all providers offer every protocol listed above.
Not all telehealth sermorelin programs operate at the same clinical standard. The difference between a quality provider and a low-quality one shows up in lab requirements, pharmacy sourcing, and how closely physicians monitor treatment. These are the factors that matter most.
A provider that prescribes sermorelin without ordering a baseline IGF-1 panel is skipping the one data point that tells the physician whether treatment is clinically indicated. Avoid any program that moves from consultation to prescription in the same session without lab work.
Green flag: IGF-1 testing before or at intakeCompounded sermorelin must come from a state-licensed sterile compounding pharmacy. The highest standard is a 503B outsourcing facility registered with the FDA. Ask the provider which pharmacy they use and confirm it is registered.
Green flag: 503A or 503B-registered pharmacySermorelin falls under hormone and metabolic medicine. Providers with background in endocrinology, internal medicine, or anti-aging medicine are better positioned to interpret lab results and adjust protocols than generalist telehealth platforms.
Green flag: Board-certified physicians on staffA quality program includes at minimum a 90-day IGF-1 follow-up to assess response and guide dose titration, consistent with the assessment intervals used in GHRH-analog clinical trials (e.g., Khorram et al., 1997). Programs that bundle labs into the plan cost more upfront but typically produce better clinical outcomes than those that bill labs separately.
Red flag: No follow-up labs after starting treatmentReputable providers publish their pricing before you speak to anyone. Watch for programs that list a low entry price but add consultation fees, lab costs, and shipping charges separately. The all-in monthly cost is what matters.
Red flag: Pricing not published before consultationSome programs offer unlimited provider messaging; others charge per check-in. If you are new to peptide therapy, access to a physician during dose titration matters. Factor in the level of ongoing support relative to cost.
Green flag: Asynchronous provider messaging includedStarting sermorelin through a telehealth provider may take 1 to 3 weeks from intake form to first injection. The process requires a physician consultation and baseline labs. Here is what that process looks like in practice.
Most telehealth platforms start with an online health questionnaire. You will share your symptoms, health history, current medications, and treatment goals. This takes 10 to 15 minutes and determines whether you qualify for a physician consultation.
A quality provider will require information to determine necessary labs (including an IGF-1 panel and others) before issuing a prescription. Some programs send you to a local lab partner; others mail a home collection kit. Your results are typically available within 3 to 5 business days and reviewed by the prescribing physician.
The consultation is conducted via video or asynchronous message, depending on the provider. The physician reviews your labs, confirms clinical indication, and determines the appropriate starting dose and protocol. This is also the time to ask about pharmacy sourcing and monitoring protocols.
Once prescribed, the compounding pharmacy prepares and ships your sermorelin vials along with injection supplies. Shipping may take 3 to 7 business days. Most programs include bacteriostatic water, syringes, and alcohol swabs.
You start at the prescribed dose and inject subcutaneously at bedtime. Most providers use a patient portal or app to track sleep, energy, and body composition changes. Follow-up schedules may vary, usually scheduled for 1 month after sermorelin initiation, with a formal lab review at 90 days.
Stopping sermorelin is not associated with a crash or withdrawal. Because the pituitary gland is not suppressed by GHRH analog use, the GH axis retains its function after treatment with sermorelin is stopped. The expected course includes a gradual return to pre-treatment GH output over several weeks. Continued progress depends on lifestyle habits maintained after stopping treatment.
Without the sermorelin signal, GH pulse frequency and amplitude return toward pre-treatment levels. Specific post-stopping timelines for sermorelin are not established in primary literature; observed timelines come from general GHRH-axis pharmacokinetics.
Without continued GH stimulation, hepatic IGF-1 production drops. The rate of decline varies by GH baseline, individual physiology, and protocol duration.
Fat regain and lean mass loss depend heavily on diet, training, and sleep habits maintained after stopping. Patients who continue resistance training and adequate protein intake retain more of their gains.
The pituitary itself is not suppressed by sermorelin use[1], which is a key pharmacological difference from exogenous HGH (Walker, 2006). The GH axis retains its ability to respond to future treatment.
Compounded sermorelin can be safe when prescribed by a licensed physician and prepared by a certified sterile compounding pharmacy. Safety is not a property of the molecule itself. Sermorelin is well-studied and carries a clean clinical record. Safety is a function of how it is sourced, prepared, and supervised. Those three factors are what separate a quality program from a problematic one.
Sermorelin is an injectable peptide. It must be prepared in a cleanroom that meets USP 797 sterility standards. Ask your provider whether their pharmacy holds a current 797 certification and when it was last inspected.
Section 503A covers traditional compounding pharmacies that prepare medications for individual patient prescriptions. Section 503B covers outsourcing facilities that can produce larger batches under direct FDA oversight. Either is acceptable; 503B provides the highest regulatory standard.
A reputable compounding pharmacy can provide a certificate of analysis (COA) confirming the purity, potency, and sterility of each batch. Providers working with quality pharmacies will share this on request without hesitation.
Compounded sermorelin can only be legally dispensed with a valid prescription from a licensed physician, nurse practitioner, or physician assistant. Platforms that offer sermorelin without a consultation are operating outside of federal law.
Reconstituted sermorelin is temperature-sensitive. Quality providers ship with cold packs and insulated packaging. Vials that arrive warm may have degraded peptide content regardless of how they appear.
Research-grade peptides sold online without a prescription are not manufactured for human use and are not subject to pharmacy sterility standards. Do not inject peptides that have not been compounded by a licensed sterile pharmacy and dispensed under a valid physician prescription.
After reviewing the providers, protocols, and outcomes covered in this guide, these are the points the editorial team flagged as most important for anyone considering sermorelin therapy.
Most controlled trials of GHRH-analog therapy run 5 to 6 months (Khorram et al., 1997[2]; Stanley 2015 tesamorelin trial[5]). The 90-day mark is the standard interval for assessing IGF-1 dose response before deciding whether to continue, titrate, or stop.
Baseline IGF-1 testing is not optional. Without it, you have no way to confirm that treatment is clinically indicated or to measure whether the patient is responding to the prescribed dose.
Combination stacks with ipamorelin[10] or CJC-1295[11] stimulate GH through additional pathways, but they are not appropriate as a starting protocol. Monotherapy at the correct dose tells you how the patient responds before adding complexity.
Compounded sermorelin from a certified 503A or 503B pharmacy[13] is appropriate for most patients. The molecule is identical. What varies is the pharmacy standard, which is why sourcing questions matter more than the compounded label itself.
Untreated hypothyroidism reduces sermorelin response[3]. This is noted in the FDA-approved Geref labeling as a precaution. Thyroid function should be confirmed before starting therapy and monitored through treatment.
This site receives advertising fees from providers listed, which may influence ranking order. Fees do not influence review scores, which are assigned independently based on clinical and operational criteria.
Patient communities on Reddit and long-form forums like Longecity have accumulated years of firsthand sermorelin experience. These are the themes that appear most consistently, drawn from thousands of threads across multiple communities.
r/Peptides, r/Sermorelin, r/Biohacking
Across forums and patient communities, deeper sleep and faster sleep onset are the most consistently reported early outcomes. Most people notice this within the first 2 to 4 weeks, well before any visible body composition changes. Some describe it as the most meaningful benefit of treatment.
r/Peptides, Longecity forums
A common theme in online discussions is that patients who stop at 8 to 12 weeks feel they did not see enough change. Users who report the strongest outcomes consistently stayed on protocol for 5 to 6 months, with the 90-day IGF-1 retest as a turning point in understanding whether their dose was therapeutic.
r/Peptides, r/Sermorelin
Several community discussions center on inconsistent results from different compounding pharmacies. Users who switched to a 503B-registered pharmacy after experiencing weak results from a lower-quality source frequently report improved response. The peptide is the same on paper; the preparation is not.
r/Peptides, r/PeptideHormones
The sermorelin and ipamorelin combination appears repeatedly as the first stack most patients try after monotherapy. Users favor it because ipamorelin does not raise cortisol or prolactin the way older GHRPs do. Many describe noticeable differences in sleep quality and recovery within the first month of the combination.
r/Sermorelin, r/Testosterone
People regularly flag programs that advertise a low starting price but add consultation fees, labs, and shipping on top. The most recommended providers in community discussions are those that publish all-in pricing before the consultation and do not require a phone call to get a quote.
r/Peptides, r/Sermorelin
Users who maintained resistance training and adequate protein after stopping sermorelin report retaining most of their lean mass improvements. Those who did not maintain these habits describe returning close to baseline within 3 to 4 months. The community consensus is that sermorelin changes what is possible, not what is permanent.
Community reports reflect self-reported patient experiences and do not constitute clinical evidence. Individual results vary. Consult a licensed physician before starting any peptide protocol.
A side-by-side breakdown of pricing, consultation type, lab monitoring, and what each provider does best.
| Provider | Starting Price | Consultation | Sermorelin Type | Lab Monitoring | HSA/FSA | Best For |
|---|---|---|---|---|---|---|
| #1 PickbmiMD | $79/mo | Online | Compounded | Included quarterly | Yes | Full-panel intake |
| Strut Health | $119/mo | Online | Compounded | Extra cost | Yes | Best value |
| SystemLabs | $179/mo | Online | Compound + stack | Included | Yes | Advanced peptides |
| Fridays Health | $259/mo | Online | Compounded | Included | No | Lifestyle support |
| PeterMD | $211.65/mo | Online | Compounded | Periodic | Yes | Men's TRT + GH |
| Embody | $99/mo | Online | Compounded | Periodic | Yes | Women's HRT + GH |
| Get Thin MD | $119/mo | Online | Compounded | Extra cost | No | Weight + GH |
| Maximus Tribe | $199.99/mo | Online | Compounded | Periodic | Yes | Men's bundles |
| RNK Health | $129/mo | Online | Compounded | Extra cost | Yes | Simple & transparent |
Pricing is based on standard monthly subscriptions. Lab monitoring inclusion varies by plan tier. Always verify current pricing with the provider directly.
Everything you need to know about sermorelin therapy before choosing a provider.
Sermorelin is a synthetic 29-amino acid analog of endogenous growth hormone-releasing hormone (GHRH). After subcutaneous injection, it binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering a pulsatile release of human growth hormone (HGH). That HGH then stimulates the liver to produce IGF-1, the downstream mediator responsible for lean mass accretion, lipolysis, sleep architecture improvement, and cellular repair. Because sermorelin acts upstream of the pituitary rather than bypassing it, the somatostatin feedback axis remains intact. The pituitary self-limits output based on circulating GH levels, which is a meaningful pharmacological distinction from exogenous somatropin.
The primary candidates are adults over 30 with symptomatic age-related growth hormone decline: reduced lean mass, increased visceral adiposity, disrupted slow-wave sleep, low energy, or slow post-exercise recovery. Confirming low or low-normal IGF-1 on a baseline lab draw before starting gives the physician a measurable baseline and avoids treating patients who do not have a deficiency. Sermorelin is contraindicated in patients with active malignancy, known pituitary tumors, proliferative diabetic retinopathy, or carpal tunnel syndrome. Patients on glucocorticoids or thyroid medications may need dose adjustments, as both affect GH axis sensitivity.
Sermorelin is injected subcutaneously, typically into the periumbilical abdomen or lateral thigh. Standard starting doses run 100–200 mcg once daily, administered at bedtime to align with the natural GH pulse that occurs during slow-wave sleep. Physicians titrate upward to 200–300 mcg based on 90-day IGF-1 results and symptom response. At higher doses, many protocols add ipamorelin (a selective ghrelin receptor agonist) or CJC-1295 without DAC to amplify the GH pulse without raising cortisol or prolactin, which are unwanted off-target effects common to older secretagogues like GHRP-6.
Compounded sermorelin through a telehealth provider runs $79 to $329 per month depending on dose, protocol complexity, and whether labs are bundled. Entry-level monotherapy programs start around $79 to $150 per month. Combination stacks with ipamorelin or CJC-1295 range from $200 to $329 per month. Programs that advertise a low entry price often add consultation fees, lab costs, and shipping separately.
The original sermorelin acetate product (Geref, Serono) held FDA approval for growth hormone deficiency in pediatric patients. That product was voluntarily withdrawn from the market in 2008 for commercial rather than safety reasons. Today, sermorelin is prescribed as a compounded formulation under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Compounded sermorelin is not FDA-approved as a finished drug product, but it can be legally prescribed by a licensed physician and dispensed by a state-licensed or FDA-registered sterile compounding pharmacy. Patients should confirm their provider uses a 503A or 503B-registered facility.
Sleep quality and energy are typically the first changes patients report, often within weeks 3–4. Body composition changes take longer: most patients see meaningful reductions in body fat percentage and measurable increases in lean mass between months 3 and 6, which aligns with when IGF-1 levels reach a new steady state. Physicians check IGF-1 at the 90-day mark to assess response and adjust dose. A full 6-month cycle is the clinical standard because sermorelin restores GH secretion gradually through pituitary stimulation rather than delivering exogenous hormone acutely. Results depend on dose adequacy, baseline IGF-1, sleep quality, protein intake, and resistance training volume.
The most common adverse effects are injection site reactions (transient redness, mild induration), flushing, headache, and lightheadedness, all of which are dose-related and most pronounced during the first few weeks of treatment. Water retention and transient joint stiffness occur in some patients at doses above 250 mcg. These generally resolve with dose reduction. Serious adverse events are rare with properly prescribed sermorelin. Because the somatostatin axis remains active, GH oversaturation and the associated risks of exogenous HGH (acromegaly, carpal tunnel syndrome, insulin resistance) are not a clinical concern at therapeutic sermorelin doses. Patients with a personal or family history of thyroid cancer should discuss contraindication risk with their physician before starting.
Synthetic HGH (recombinant somatropin) bypasses the pituitary entirely and delivers growth hormone directly into circulation. It produces faster and larger increases in IGF-1 than sermorelin, which is clinically relevant in severe adult GH deficiency. The tradeoffs are significant: somatropin costs $600–$2,000 per month, requires more precise dosing to avoid supraphysiologic GH levels, and carries higher rates of fluid retention, carpal tunnel syndrome, and insulin resistance. Sermorelin preserves the somatostatin feedback loop, so the pituitary moderates output and physiologic GH levels are less likely to be exceeded. For adults with age-related rather than pathologic GH decline, sermorelin is the more appropriate first-line option. Somatropin is indicated when pituitary function is insufficient to respond to secretagogue stimulation.
Our editorial team evaluates every provider across six independently weighted criteria. Scores are not influenced by advertising relationships.
We evaluated board certification, physician specialization in hormone therapy, and quality of the initial consultation and ongoing monitoring protocols.
We assessed monthly subscription costs, what is included at each tier, upfront vs. hidden fees, and whether HSA/FSA payments are accepted.
We reviewed whether providers follow evidence-based dosing protocols, offer combination peptide therapy, and perform baseline IGF-1 testing before prescribing.
We verified that providers source compounded sermorelin from state-licensed 503A or FDA-registered 503B compounding pharmacies using sterile manufacturing standards.
We scored provider messaging response times, availability of dedicated health coaches, platform usability, and how quickly new patients receive their first prescription.
We analyzed verified patient reviews, reported IGF-1 improvement rates, symptom resolution feedback, and long-term retention in sermorelin therapy programs.
